Your search for supplemental oxygen returned 2 results

Findings showed that the trial did not meet statistical significance on the primary endpoint.

FibroGen announced data from its Phase 2a study of FG-4592 (oral anemia therapy) in patients with stage 3-4 chronic kidney disease (CKD) and anemia.